Literature DB >> 16048961

Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.

Ernest J Mui1, David Jacobus, Wilbur K Milhous, Guy Schiehser, Honghue Hsu, Craig W Roberts, Michael J Kirisits, Rima McLeod.   

Abstract

The triazine WR99210 [4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2,4,5-trichlorophenoxypropyloxy)-1,3,5 triazine] inhibits Toxoplasma gondii in vitro at nanomolar levels (P < 0.05). The 50% inhibitory concentration (IC(50)) was approximately 50 nM. It is a potent inhibitor in vitro and is also effective in vivo. Administration of WR99210 parenterally (i.e., intraperitoneally) reduced the mean number of RH strain tachyzoites present in peritoneal fluid substantially 4 days after intraperitoneal infection of mice. There was a mean of approximately 35 million parasites in control mice as contrasted with approximately 2 million parasites in mice treated with 1.25 mg WR99210/kg of body weight in a representative experiment (P < 0.05). In addition the prodrug PS-15 N'-[3-(2,4, 5-trichlorophenoxy)propyloxy]-N9-(1-methylethyl) imidocarbonimidicdiamide is converted to 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2,4,5-trichlorophenoxypropyloxy)-1,3,5 triazine in vivo when the prodrug is administered orally. PS-15 administered by gavage also reduced intraperitoneal RH strain T. gondii tachyzoite numbers. WR99210 has high efficacy and relatively low toxicity because of its substantial effect on T. gondii dihydrofolate reductase (DHFR) but not the mammalian host DHFR. Amino acid sequences of T. gondii, Plasmodium falciparum, and Homo sapiens DHFRs were compared. It is of interest that of the DHFR amino acids considered to be interacting with WR99210 in P. falciparum within interatomic distances within 3 to 5 A, four of eight were shared with T. gondii DHFR. H. sapiens also shared four amino acids thought to be interacting with WR99210. Efficacy of intraperitoneal administration of WR99210 and peroral administration of PS-15 demonstrate the potential usefulness of this class of compounds in treatment of toxoplasmosis administered either parenterally or perorally. The recent development program for this class of antimicrobials as antimalarials makes our proof of principle of improved efficacy of triazines (compared with the gold standard treatment, pyrimethamine) against T. gondii especially promising.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048961      PMCID: PMC1196210          DOI: 10.1128/AAC.49.8.3463-3467.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Insights into antifolate resistance from malarial DHFR-TS structures.

Authors:  Jirundon Yuvaniyama; Penchit Chitnumsub; Sumalee Kamchonwongpaisan; Jarunee Vanichtanankul; Worachart Sirawaraporn; Paul Taylor; Malcolm D Walkinshaw; Yongyuth Yuthavong
Journal:  Nat Struct Biol       Date:  2003-05

2.  Prized malaria drug target nailed.

Authors:  Pradipsinh K Rathod; Margaret A Phillips
Journal:  Nat Struct Biol       Date:  2003-05

3.  Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.

Authors:  M Brun-Pascaud; F Chau; L Garry; D Jacobus; F Derouin; P M Girard
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.

Authors:  D A Fidock; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria.

Authors:  D S Peterson; W K Milhous; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Analogues of N-benzyloxydihydrotriazines: in vitro antimalarial activity against Plasmodium falciparum.

Authors:  G E Childs; C Lambros
Journal:  Ann Trop Med Parasitol       Date:  1986-04

7.  In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii.

Authors:  E Holfels; J McAuley; D Mack; W K Milhous; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists.

Authors:  C J Canfield; W K Milhous; A L Ager; R N Rossan; T R Sweeney; N J Lewis; D P Jacobus
Journal:  Am J Trop Med Hyg       Date:  1993-07       Impact factor: 2.345

9.  Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine.

Authors:  Michele D Hastings; Kathryn M Porter; Jason D Maguire; Ika Susanti; Winni Kania; Michael J Bangs; Carol Hopkins Sibley; J Kevin Baird
Journal:  J Infect Dis       Date:  2004-02-04       Impact factor: 5.226

10.  In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.

Authors:  P A Winstanley; E K Mberu; I S Szwandt; A M Breckenridge; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

View more
  15 in total

1.  Phenotypic and gene expression changes among clonal type I strains of Toxoplasma gondii.

Authors:  Asis Khan; Michael S Behnke; Ildiko R Dunay; Michael W White; L David Sibley
Journal:  Eukaryot Cell       Date:  2009-10-02

2.  Salicylanilide inhibitors of Toxoplasma gondii.

Authors:  Alina Fomovska; Richard D Wood; Ernest Mui; Jitenter P Dubey; Leandra R Ferreira; Mark R Hickman; Patricia J Lee; Susan E Leed; Jennifer M Auschwitz; William J Welsh; Caroline Sommerville; Stuart Woods; Craig Roberts; Rima McLeod
Journal:  J Med Chem       Date:  2012-09-26       Impact factor: 7.446

3.  Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach.

Authors:  Sandhya Kortagere; Ernest Mui; Rima McLeod; William J Welsh
Journal:  J Comput Aided Mol Des       Date:  2011-02-26       Impact factor: 3.686

4.  Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.

Authors:  Suresh K Tipparaju; Stephen P Muench; Ernest J Mui; Sergey N Ruzheinikov; Jeffrey Z Lu; Samuel L Hutson; Michael J Kirisits; Sean T Prigge; Craig W Roberts; Fiona L Henriquez; Alan P Kozikowski; David W Rice; Rima L McLeod
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

5.  Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids.

Authors:  Ruth Welti; Ernie Mui; Alexis Sparks; Sarah Wernimont; Giorgis Isaac; Michael Kirisits; Mary Roth; Craig W Roberts; Cyrille Botté; Eric Maréchal; Rima McLeod
Journal:  Biochemistry       Date:  2007-11-08       Impact factor: 3.162

Review 6.  Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.

Authors:  Madalyn M McFarland; Sydney J Zach; Xiaofang Wang; Lakshmi-Prasad Potluri; Andrew J Neville; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

7.  Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.

Authors:  Jozef Stec; Alina Fomovska; Gustavo A Afanador; Stephen P Muench; Ying Zhou; Bo-Shiun Lai; Kamal El Bissati; Mark R Hickman; Patty J Lee; Susan E Leed; Jennifer M Auschwitz; Caroline Sommervile; Stuart Woods; Craig W Roberts; David Rice; Sean T Prigge; Rima McLeod; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2013-06-14       Impact factor: 3.466

8.  Effects of Thymus vulgaris ethanolic extract on chronic toxoplasmosis in a mouse model.

Authors:  Maysa Ahmad Eraky; Amany Farouk El-Fakahany; Nagwa Mostafa El-Sayed; Eman Abdel-Rahman Abou-Ouf; Doaa Ibrahim Yaseen
Journal:  Parasitol Res       Date:  2016-04-20       Impact factor: 2.289

9.  Evaluation of the anti-Toxoplasma gondii Activity of Hederagenin in vitro and in vivo.

Authors:  Run-Hui Zhang; Runhao Jin; Hao Deng; Qing-Kun Shen; Zhe-Shan Quan; Chun-Mei Jin
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

10.  Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo.

Authors:  Ernest J Mui; Guy A Schiehser; Wilbur K Milhous; Honghue Hsu; Craig W Roberts; Michael Kirisits; Stephen Muench; David Rice; J P Dubey; Joseph W Fowble; Pradipsinh K Rathod; Sherry F Queener; Susan R Liu; David P Jacobus; Rima McLeod
Journal:  PLoS Negl Trop Dis       Date:  2008-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.